The United Kingdom and the United States have concluded a landmark commercial pact that will maintain zero import taxes on British drug exports being sold in the American market.
The Terms of the Accord
As part of the deal, the UK has agreed to raise expenditure on medicines through the National Health Service (NHS). This pledge guarantees that import taxes on these vital goods will be held at nothing for a duration of three years.
This deal follows recent warnings to hike tariffs on patented pharmaceutical imports, with increases discussed as high as 100%.
"This arrangement between the Britain strengthens the international landscape for new treatments and establishes much-needed equity to transatlantic drug exports," a release noted.
Trade Impact
Drugs are one of the UK's biggest export categories to the United States, which is clearly the biggest destination for leading British pharmaceutical firms.
Trade data show that in the one-year period to the end of the third quarter, the UK sold drugs valued at £11.1bn to the US. This amount accounted for 17.4% of total UK exports in that span.
"This agreement safeguards employment, stimulates funding and sets the stage for the UK to emerge as a worldwide center for biotech and pharma," the Business and Trade Secretary commented.
Specific NHS Changes
The agreement involves several key commitments from the British government:
- Higher Cost Ceiling: The UK will raise the affordability limit at which it judges new medicines to be prohibitively costly by twenty-five percent.
- Boosted Medicine Funding: There is a target to double overall NHS spending on drugs from 0.3 percent of Gross Domestic Product to 0.6 percent over the coming ten years.
- Refund Ceiling: The amount drug companies must return to the NHS to stay within budget will be limited at fifteen percent. Last year, rebates were more than 20%.
Industry Background
This agreement takes place against a protracted tension between the sector and the ministers over drug pricing and approval rates.
This friction were exacerbated by claims that US patients were paying a premium for the identical medicines than consumers in the Britain and the EU.
Over the last 18 months, several major pharmaceutical investments in the UK have been delayed or abandoned, while major expansions have been announced toward American operations.
One official stated that the NHS must spend more on treatments, noting that its expenditure on drugs had shrunk as a proportion of its overall budget over the previous ten-year period.
